The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR® analysis

[1]  É. Azoulay,et al.  Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. , 2014, Medecine et maladies infectieuses.

[2]  D. Boutoille,et al.  Pneumocystis jirovecii pneumonia in HIV-negative patients: A prospective study with focus on immunosuppressive drugs and markers of immune impairment , 2014, Scandinavian journal of infectious diseases.

[3]  B. de Sousa,et al.  (1–3)-Beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  S. Ichiyama,et al.  Pneumocystis polymerase chain reaction and blood (1→3)-β-D-glucan assays to predict survival with suspected Pneumocystis jirovecii pneumonia. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  M. Aricò,et al.  Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. , 2014, The Journal of pediatrics.

[6]  J. Kanne,et al.  Thoracic infections in immunocompromised patients. , 2014, Radiologic clinics of North America.

[7]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[8]  K. Kable,et al.  Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Huiping Li,et al.  Evaluation of PCR in Bronchoalveolar Lavage Fluid for Diagnosis of Pneumocystis jirovecii Pneumonia: A Bivariate Meta-Analysis and Systematic Review , 2013, PloS one.

[10]  J. Brion,et al.  Pneumocystis jirovecii (Pj) quantitative PCR to differentiate Pj pneumonia from Pj colonization in immunocompromised patients , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  P. Macdonald,et al.  Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem? , 2013, Kidney international.

[12]  S. Le Gal,et al.  Combined Quantification of Pulmonary Pneumocystis jirovecii DNA and Serum (1→3)-β-d-Glucan for Differential Diagnosis of Pneumocystis Pneumonia and Pneumocystis Colonization , 2013, Journal of Clinical Microbiology.

[13]  V. Cody,et al.  Trimethoprim Resistance of Dihydrofolate Reductase Variants from Clinical Isolates of Pneumocystis jirovecii , 2013, Antimicrobial Agents and Chemotherapy.

[14]  G. Nichols,et al.  Increasing Pneumocystis Pneumonia, England, UK, 2000–2010 , 2013, Emerging infectious diseases.

[15]  S. Krause,et al.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors , 2013, Annals of Hematology.

[16]  S. Tasaka,et al.  Recent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adults. , 2013, Expert opinion on medical diagnostics.

[17]  S. Tasaka,et al.  Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[18]  A. Nager,et al.  Rising incidence of Pneumocystis jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. , 2012, Journal of medical microbiology.

[19]  A. Morris,et al.  Colonization by Pneumocystis jirovecii and Its Role in Disease , 2012, Clinical Microbiology Reviews.

[20]  J. Passweg,et al.  Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal , 2011, Bone Marrow Transplantation.

[21]  H. Masur,et al.  Regionally limited or rare infections: prevention after hematopoietic cell transplantation , 2010, Bone Marrow Transplantation.

[22]  M. Ramesh,et al.  Effective alternates to trimethoprim‐sulfamethoxazole as antimicrobial prophylaxis in stem cell recipients: Are there any? , 2008, Pediatric transplantation.

[23]  S. Asano,et al.  No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[24]  S. Y. Kim,et al.  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients , 2008, Pediatric blood & cancer.

[25]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[26]  R. Gress,et al.  T cell immune reconstitution following lymphodepletion. , 2007, Seminars in immunology.

[27]  P. Grossi,et al.  Efficacy of Caspofungin Addition to Trimethoprim-Sulfamethoxazole Treatment for Severe Pneumocystis Pneumonia in Solid Organ Transplant Recipients , 2007, Transplantation.

[28]  M. Labopin,et al.  Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.

[29]  C. Pui,et al.  Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia , 2007, Cancer.

[30]  J. Helweg-Larsen,et al.  Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002–2004 , 2007, Scandinavian journal of infectious diseases.

[31]  S. Shankar,et al.  Management of Pneumocystis jiroveci Pneumonia in Children Receiving Chemotherapy , 2007, Paediatric drugs.

[32]  R. Andersson,et al.  Pneumocystis pneumonia--a retrospective study 1991-2001 in Gothenburg, Sweden. , 2006, The Journal of infection.

[33]  B. Afessa,et al.  Major complications following hematopoietic stem cell transplantation. , 2006, Seminars in respiratory and critical care medicine.

[34]  D. Kontoyiannis,et al.  Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[35]  F. Derouin,et al.  Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study , 2005, Bone Marrow Transplantation.

[36]  B. Storer,et al.  Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  L. Mileshkin,et al.  An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital , 2005, British Journal of Cancer.

[38]  J. Hoyer,et al.  Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (Cb5R) enzyme levels , 2005, Pediatric blood & cancer.

[39]  J. Fishman,et al.  Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients , 2004, Clinical Microbiology Reviews.

[40]  N. Ansari,et al.  Pneumocystis carinii infection. Update and review. , 2004, Archives of pathology & laboratory medicine.

[41]  S. Lee,et al.  Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea , 2004, Bone Marrow Transplantation.

[42]  J. Fishman,et al.  Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. O'Connor.  The Cochrane Database of Systematic Reviews , 2004 .

[44]  J. Lipton,et al.  Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[45]  J. Fishman,et al.  Prevention of infection caused by Pneumocystis carinii in transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  K. Strålin,et al.  Clinical significance of nested polymerase chain reaction and immunofluorescence for detection of Pneumocystis carinii pneumonia. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[47]  G. Papanicolaou,et al.  Pneumocystis carinii Pneumonia prophylaxis with atovaquone in trimethoprim‐sulfamethoxazole–intolerant orthotopic liver transplant patients: A preliminary study , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[48]  S. Mineishi,et al.  Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation , 2001, American journal of hematology.

[49]  M. Wahlgren,et al.  Genotypes of clustered cases of Pneumocystis carinii pneumonia. , 2001, Scandinavian journal of infectious diseases.

[50]  S. Levine,et al.  Pneumocystis carinii pneumonia in patients without HIV infection. , 2001, The American journal of the medical sciences.

[51]  R. Straub,et al.  Pneumocystis carinii Pneumonia as a Complication of Immunosuppressive Therapy , 2000, Infection.

[52]  M. Vasconcelles,et al.  Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  S. Crawford,et al.  High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  J. Fishman,et al.  A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[55]  C. Dykewicz.  Preventing opportunistic infections in bone marrow transplant recipients , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[56]  N. Kröger,et al.  Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases , 1999, Bone Marrow Transplantation.

[57]  D. Petropoulos,et al.  Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation , 1997, Bone Marrow Transplantation.

[58]  K. Whyte,et al.  Discrimination against people with HIVinfection and AIDS , 1994, BMJ.

[59]  G. Ehninger,et al.  Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. , 1993, Bone marrow transplantation.

[60]  D. Weisdorf,et al.  Pneumocystis carinii pneumonitis following bone marrow transplantation. , 1992, Bone marrow transplantation.

[61]  D. Hawksworth,et al.  Pneumocystis carinii shows DNA homology with the ustomycetous red yeast fungi , 1992, Molecular microbiology.

[62]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.

[63]  Lee-Jen Wei,et al.  Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations , 1992 .

[64]  Related Topics,et al.  Survival analysis : state of the art , 1992 .

[65]  D. Friend,et al.  Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. , 1987, The American review of respiratory disease.

[66]  B. Burke,et al.  PNEUMOCYSTIS CARINII INFECTION , 1973, Medicine.